Showing 2531-2540 of 4063 results for "".
- American Academy of Optometry Foundation Now Accepting Applications for 2023 Residency Awardshttps://modernod.com/news/american-academy-of-optometry-foundation-now-accepting-applications-for-2023-residency-awards/2481516/The American Academy of Optometry Foundation is accepting requests for applications for its 2023 Residency Awards. Applications must be received by Tuesday, June 1, 2023. Award opportunities include: Douglas Hopkins Primary Care Eye Residency Award&nb
- Endogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of RPhttps://modernod.com/news/endogena-therapeutics-completes-dose-escalation-in-the-phase-12a-clinical-trial-of-ea-2353-for-the-treatment-of-retinitis-pigmentosa/2481511/Endogena Therapeutics announced that the dose-escalation stage of its phase 1/2a study of EA-2353 in retinitis pigmentosa (RP) has been successfully completed. No clinically relevant or dose-limiting adverse events were identified after repeated intravitreal injections. Given the positive sa
- Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b Trial of Optogenetic Therapy for RPhttps://modernod.com/news/nanoscope-therapeutics-announces-positive-topline-results-from-phase-2b-trial-of-optogenetic-therapy-for-rp/2481504/Nanoscope Therapeutics announced topline results from the phase 2b RESTORE clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration in advanced retinitis pigmentosa (RP), irrespective of gene mutation. MCO-0
- RG6501 (OpRegen) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summithttps://modernod.com/news/rg6501-opregen-phase-12a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit/2481476/Lineage Cell Therapeutics announced that results from a phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the
- LumiThera Announces Sustained Vision Improvement for 24 Months in Dry AMD Subjects from US LIGHTSITE III Trialhttps://modernod.com/news/lumithera-announces-sustained-vision-improvement-for-24-months-in-dry-amd-subjects-from-us-lightsite-iii-clinical-trial-data/2481469/LumiThera announced 24-month data from its LIGHTSITE III multicenter clinical trial which demonstrated sustained vision improvement in dry age-related macular degeneration (AMD) subjects treated with the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked
- iSTAR Medical Initiates International STAR-VI Trial for the Use of MINIject in Conjunction with Cataract Surgeryhttps://modernod.com/news/istar-medical-initiates-international-star-vi-trial-for-the-use-of-miniject-in-conjunction-with-cataract-surgery/2481466/iSTAR Medical announced that the first patients have been implanted in its STAR-VI international trial evaluating the safety and efficacy of MINIject` in conjunction with cataract surgery in patients with primary open-angle glaucoma. iSTAR Medical’s STAR-VI trial is a pr
- Visionix Unveils Second Generation VX 650 Multimodal Screener at Vision Expo 2023https://modernod.com/news/visionix-unveils-second-generation-vx-650-multimodal-screener-at-vision-expo-2023/2481461/Visionix announces a new multimodal device update with its second-generation VX 650. Launched in 2021, the VX 650 is an advanced anterior segment analyzer with retinal imaging. The enhanced wavefront-based aberrometer's "quick mode" and new capture flexibilities can decrease screeni
- Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meetinghttps://modernod.com/news/kiora-pharmaceuticals-announces-the-acceptance-of-three-abstracts-at-the-2023-arvo-annual-meeting/2481458/Kiora Pharmaceuticals announced three abstract acceptances for oral and poster presentation at the 2023 Association for Research in Vision and Ophthalmology (ARVO) meeting in New Orleans, April 23-27, 2023. Further results from each of these three studies will be reported at the conference.<
- Phase 1/2a Results of Lineage Cell's Retinal Pigment Epithelium Cell Transplant Therapy to Be Featured at ARVO Annual Meetinghttps://modernod.com/news/phase-12a-results-of-lineage-cells-retinal-pigment-epithelium-cell-transplant-therapy-to-be-featured-at-arvo-annual-meeting/2481451/Lineage Cell Therapeutics announced that results from imaging analyses of structural changes in addition to visual data from a phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting in New Orleans.
- Envision University Sets Agenda for In-Person Spring 2023 Conferencehttps://modernod.com/news/envision-university-sets-agenda-for-in-person-spring-2023-conference/2481426/The agenda has been set for the Envision Conference West, which will be held in collaboration with UT Health Department of Occupational Therapy, March 30-April 1, 2023, at the Academic Learning and Teaching Center of UT Health in San Antonio, Texas. The Envision Conference is the only multid